Physician profile
John Joseph
NPI 1801828074
$2,972.35
in general payments reported to CMS, 2019-2025
22 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $111 · 2021: $219 · 2022: $357 · 2023: $203 · 2024: $687 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756 · Travel and Lodging: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.29 |
| Travel and Lodging | $223.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $598.60 | 2019-2025 | |
| Nalu Medical, INC. | $451.92 | 2024 | Nalu Neurostimulation System |
| Saluda Medical Americas, INC. | $392.79 | 2025 | Evoke |
| Teva Pharmaceuticals USA, INC. | $214.97 | 2020-2025 | |
| Collegium Pharmaceutical, INC. | $181.45 | 2021-2025 | Belbuca |
| Stimwave Technologies Incorporated | $180.43 | 2019 | |
| Tersera Therapeutics LLC | $146.00 | 2022-2024 | Prialt |
| Si-Bone, INC. | $139.07 | 2025 | |
| Boston Scientific Corporation | $131.14 | 2023-2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.50 | 2025 | Jardiance |
| Ibsa Pharma INC. | $97.80 | 2022-2024 | Tirosint, Licart, Licart |
| Lilly USA, LLC | $46.82 | 2021 | |
| Averitas Pharma INC. | $44.88 | 2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $39.76 | 2024-2025 | Spravato |
| Hikma Pharmaceuticals USA | $35.00 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.89 | 2022 | |
| Pfizer INC. | $32.23 | 2023 | |
| Tonix Medicines, INC. | $23.68 | 2025 | Tonmya |
| Foundation Fusion Solutions, LLC | $17.46 | 2025 | |
| Braeburn INC. | $17.00 | 2025 | Brixadi |
| Biodelivery Sciences International, INC. | $12.00 | 2021 | |
| Electronic Waveform Lab, INC. | $9.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.